Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (391-400 of 598) with videos related to

Pageof 60
Sort By:
Blood Cancer Journal|January 8, 2021
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathwayAntonella Padella, Maria Chiara Fontana, Giovanni Marconi, et al.
Haematologica|March 3, 2009
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia veraSusanne Schnittger, Ulrike Bacher, Claudia Haferlach, et al.
Journal of Leukocyte Biology|September 17, 2013
The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APLMagali Humbert, Elena A Federzoni, Adrian Britschgi, et al.
Journal of Cancer Research and Clinical Oncology|November 5, 2014
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phaseKaterina Machova Polakova, Vojtech Kulvait, Adela Benesova, et al.
Haematologica|March 4, 2017
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasmMohamad Jawhar, Juliana Schwaab, Manja Meggendorfer, et al.
Stroke|February 15, 2023
Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With StrokeErnst Mayerhofer, Christoph Strecker, Heiko Becker, et al.
JCO Clinical Cancer Informatics|May 9, 2024
Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and MicrosimulationCaterina Gregorio, Marta Spreafico, Saverio D'Amico, et al.
Journal of Hematopathology|October 9, 2025
Analysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutationsKonnie M Hebeda, Ludmila Boudová, Maarten F Corsten, et al.
Leukemia|November 30, 2021
Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasiaSunisa Kongkiatkamon, Simona Pagliuca, Vera Adema, et al.
Blood|February 7, 2012
Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignanciesLeonie I Kroeze, Gorica Nikoloski, Pedro da Silva-Coelho, et al.
Pageof 60

Showing results (391-400 of 598) with videos related to

Sort By:
Pageof 60
Blood Cancer Journal|January 8, 2021
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathwayAntonella Padella, Maria Chiara Fontana, Giovanni Marconi, et al.
Haematologica|March 3, 2009
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia veraSusanne Schnittger, Ulrike Bacher, Claudia Haferlach, et al.
Journal of Leukocyte Biology|September 17, 2013
The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APLMagali Humbert, Elena A Federzoni, Adrian Britschgi, et al.
Journal of Cancer Research and Clinical Oncology|November 5, 2014
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phaseKaterina Machova Polakova, Vojtech Kulvait, Adela Benesova, et al.
Haematologica|March 4, 2017
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasmMohamad Jawhar, Juliana Schwaab, Manja Meggendorfer, et al.
Stroke|February 15, 2023
Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With StrokeErnst Mayerhofer, Christoph Strecker, Heiko Becker, et al.
JCO Clinical Cancer Informatics|May 9, 2024
Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and MicrosimulationCaterina Gregorio, Marta Spreafico, Saverio D'Amico, et al.
Journal of Hematopathology|October 9, 2025
Analysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutationsKonnie M Hebeda, Ludmila Boudová, Maarten F Corsten, et al.
Leukemia|November 30, 2021
Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasiaSunisa Kongkiatkamon, Simona Pagliuca, Vera Adema, et al.
Blood|February 7, 2012
Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignanciesLeonie I Kroeze, Gorica Nikoloski, Pedro da Silva-Coelho, et al.
Pageof 60